Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza A (H5N1) vaccine (clade 2)
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The influenza A (H5N1) vaccine (clade 2) is an inactivated, split-virion vaccine developed by Sanofi Pasteur for active immunization against H5N1 avian influenza. Specifically designed to target clade 2 H5N1 strains, including variants from Indonesia (clade 2.1) and China (clades 2.2 and 2.3), the vaccine induces neutralizing antibodies against the viral hemagglutinin (HA) protein. This mechanism blocks the virus from entering human cells, providing protection against infection. Developed between 2006 and 2008 as part of the U.S. government's pandemic preparedness strategy, the vaccine was manufactured at Sanofi's Swiftwater facility and supplied to the Strategic National Stockpile. It is administered via intramuscular injection and was not intended for commercial retail sale.
- Other names
- H5N1 clade 2 vaccineH-5N1 clade 2 vaccineH 5N1 clade 2 vaccineSanofi H5N1 clade 2 vaccineIndonesia/China H5N1 vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on influenza A (H5N1) vaccine (clade 2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza A (H5N1) vaccine (clade 2).